The global vaccine race is still hot, as the new crown DNA vaccine suffers.

TextOn June 30, Inovio Pharmaceuticals (NASDAQ:INO) announced interim results from phase I clinical trials of a DNA vaccine that encodes the new coronavirus sting protein, and after two doses of the INO-4800 vaccine, 34 of the 36 subjects (94%) had an "overall immune response" at week 6 and had no serious adverse events in eight weeksInovio was eager for a big rally in the stock market, but capital markets didn't seem to be buying the results, falling 15 per cent to $26.95 by the day's closeChart 1Inovio's share price declined after the release of Phase I clinical results
Inovio's release of Phase I Clinical Trials (NCT4336410) data, while positive, did not report quantitative measurements of antibody titer or T-cell response, only observed body fluid and cellular immune responsesInovio's press release cites two studies published this year showing that 33-40% of patients with recovery have lower levels of neutralizing antibodies than detectable levels, which seems to indicate the importance of Inovio's deliberate dilution of neutralizing antibodiesthe prevailing view in the industry that neutralizing antibodies is a key component in protecting the body from neo-coronavirus infection, the performance of the vaccine in preclinical and clinical studies is primarily assessed by neutralizing antibody titerThis view is widely accepted by investors that neutralizing antibody titer is a key benchmark for determining the effectiveness of the new crown vaccineInovio, then, is in the midst of a cold ride in the capital marketsIn fact, it is not clear how different titer is related to the severity or level of protection of the disease, the FDA recommends a recovery period of plasma titer 160May 18 U.Stime, the well-known Moderna Corporation (NASDAQ:MRNA) released interim data on the phase I clinical trial of the new coronavaccinee, mRNA-1273 (NCT04283461), which showed that the vaccine was able to induce antibodies in 45 healthy volunteers, and that neutralizing the amount of varied and the average amount of blood drops in the recovery period was similar to that of the eight volunteers who were able to assess the level of the antibodyModerna has therefore been criticized for lack of detailThen, more than a month later, Inovio's move can be described as a "top wind crime."while Inovio's lack of detail sourcing of phase I clinical mid-clinical data is cold, his new vaccine may be doing wellOn July 1, U.S time, BioNTech/Pfizer released data from the ongoing Phase I/II clinical trial of the new crownmRNA vaccine BNT162b1, in which 36 subjects aged 18-55 developed strong neutralizing antibody levels in 36 subjects 14 days after their second injection BioNTech's new crown mRNA vaccine project BNT162, in collaboration with Pfizer, includes four different variants, of which b1 variant (BNT162b1) is a nanoparticle formulation and nucleoside modification, coding the new coronavirus plycoprotein receptor binding domain (RBD) tripolymer to enhance immunogenicity Chart 2 The BNT162 project included four variants
45 subjects were selected from 76 participants, and were randomly divided into 3 dose groups (10, 30, 100 ?g), with 3 subjects injected with a placebo The 1st and 21st dosedoses were injected on the first and 21st days, respectively, and the 100?g dose group was injected with the first dose on the first day on the 21st day, the average average concentration of RBD binding antibodies (GMC) of 36 subjects receiving the first dose was 534-1778 units/ml, 0.9 to 2.9 times the 602 units/ml level of the healing serum (HCS) level After receiving a second dose in two low-dose groups (10?g, 30 ?g), the average geometric concentration of RBD binding antibodies for the 24 subjects ranged from 4813-27872 units/ml on the 28th day, 8 times the recovery serum (HCS) level of 602 units/ml to 46.3 times On the 28th day, the newly crowned virus neutralized the antibody geometric average titness (GMT) reached 168 and 267 in the 10?g and 30?g dose groups, respectively, which is 1.8 and 2.8 times that of the neutralized antibody titer 94 in the healing period serum (HCS) (Figure 3) Chart 3 The geometric average concentration of RBD in combination with IgG after injection and the neutrality of the titer 50% of the new coronavirus While it is not clear whether the BNT162b1 vaccine will actually be effective in preventing new coronavirus infections, at least the clinical trial data are encouraging As a result, both Pfizer and BioNTech's share prices rose Inovio, while losing, need not be too pessimistic, as a mid-term result of Phase I clinical trials, and possibly more and better clinical trial data The results of the Phase I clinical trial (NCT04313127) of The Ad5-nCoV, a danovirus vector vaccine in China, were also not satisfactory 108 volunteers were injected in one of three doses, but only 50-75% of the subjects produced neutralizing antibody levels that were considered high enough the global competition for new-crown vaccine research and development is still in the heat of the world, the industry is looking forward to more new vaccine data First, the other three variants of the BNT162 project (a1, b2, c2) should soon produce Phase I results, and AZD122, a viral vector vaccine developed by AstraZeneca in collaboration with Oxford University, has been tested in 1,000 patients and is expected to be announced in July In addition, there are a number of new crown vaccine trial data to be published soon, see Chart 4 Chart 4 Global in the development of a new coronavirus vaccine (partially) So where should we focus when the clinical data on the new crown vaccine are released? neutralizing the level of antibodies, at least to reach the level in the recovery period serum, generally higher the better This article is crucial Given that the new coronavirus vaccine will be used in a very wide range of populations, safety is also important to ensure that there are no inflammatory symptoms and to keep a close eye on adverse events disclosed in the data In addition to antibody-based body fluid immunity, it may also be important that vaccines can cause T-cell reactions Both body fluid immunity and cellular immunity may be necessary to prevent new coronavirus infections the development of a new crown vaccine still has a lot of work to do, and more need to consider accelerating the development process as the global epidemic continues to progress There is a view in the industry that the global economic order will not be able to return completely to normal until countries are able to completely get rid of social constraints until a new vaccine is available Therefore, the development of the new crown vaccine is of great significance.